Table 4.
Published trials and observational studies showing side effects of the COVID-19 vaccines included in this systematic review.
| Study | Total no. | Local effects (% of first dose vaccine recipients) | Systemic effects (% of first dose vaccine recipients) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pain | Redness | Swelling | Fever | Fatigue | Headache | Chill | Vomiting | Diarrhea | Nausea | Arthralgia | ||
| Adenovirus vector vaccines | ||||||||||||
| Zhu et al. (19) | 108 | 54 | 4 | 7 | 46, 8 a | 44, 2 a | 39 | 0 | 2 | 11 | 6 | 17, 1 a |
| Zhu et al. (20) | 253 | 57 | 2 | 4, <1 a | 32, 8 a | 42, 1 a | 29, 1 a | 0 | 2 | 8 | 8 | 13, 1 a |
| Folegatti et al. (16) | 487 | 67 | 0 | 0 | 70 | 15 | 68 | 56 | 0 | 0 | 20 | 0 |
| Logunov et al. (17) | 9 | 78 | 0 | 0 | 89 | 33 | 67 | 0 | 0 | 11 | 22 | 33 |
| Logunov et al. (17) | 20 | 40 | 0 | 5 | 95 | 55 | 45 | 0 | 0 | 15 | 5 | 20 |
| Ramasamy et al. (18) | 98 | 39 | 0 | 0 | <1 | 20, 3 a | 10 | 10, <1 a | 0 | 0 | <2 | <1 |
| Sadoff et al. (37) | 21,895 | 0.2 | 0.1 | 0.1 | 0.2 | 1 | 0.7 | 0 | 0 | 0 | 0.2 | 0 |
| Menni et al. (33) | 345,280 | 19 | 4.2 | 5.5 | 8.2 | 21 | 23 | 14.7 | 0 | 2.2 | 5.7 | 11.5 |
| mRNA vaccines | ||||||||||||
| Mulligan et al. (23) | 45 | 85 | 10 | 15 | 21 | 55, 4 a | 52, 2 a | 42, <1 a | 0 | 6 | 0 | 27 |
| Walsh et al. (28) | 84 | 75 | 17 | 21 | 5 | 50 | 0 | 35 | 0 | 0 | 0 | 0 |
| Walsh et al. (28) | 84 | 70, <2 a | <1 | <1 | 6 | 40 | 0 | 31 | 0 | 0 | 0 | 0 |
| Anderson et al. (21) | 40 | 75 | 10 | 18 | 0 | 35 | 30 | 0 | 0 | 0 | 0 | 0 |
| Polack et al. (27) | 18 860 | 80 | 5 | 6 | 10 | 40 | 35 | 20 | <1 | 6 | 0 | 13 |
| Baden et al. (40) | 15 181 | 70, 4 a | 4 | 5 | 0 | 50 | 30 | 0 | 7 | 0 | 8 | 35 |
| Menni et al. (33) | 282 103 | 29 | 4 | 6.4 | 1.5 | 8.4 | 7.8 | 2.5 | 0 | 1.2 | 2.1 | 3.2 |
| Monin et al. (42) | 40 | 52 | 20 | 7 | 2 | 20 | 15 | 10 | 4 | 3 | 1 | 10 |
| Subunit vaccines | ||||||||||||
| Keech et al. (22) | 23 | 42 | 0 | 0 | 0 | 40 | 40, 5 a | 0 | 0 | 0 | 5 | 10 |
| Chappell et al. (29) | 24 | 41 | 0 | 0 | 0 | 15 | 30 | 12 | 4 | 11 | 5 | 10 |
| Inactivated virus vaccines | ||||||||||||
| Xia et al. (24) | 24 | 29 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Zhang et al. (35) | 24 | 20 | 5 | 5 | 5 | 0 | 5 | 0 | 0 | 5 | 0 | 57 |
| Wu et al. (34) | 125 | 12 | 11 | 1 | 3 | 3 | 0 | 0 | 0 | 2 | 1 | 0 |
a
Grade 3. Grade 1 and 2 side effects increased after the second dose in the groups taking the mRNA and adenovirus vector vaccines. Grades of health effects were defined by previously published works.